ライフサイエンスコーパス: pharmacogenetic study

1 ance of maximizing adherence to treatment in pharmacogenetic studies.

2 ns of drug metabolism in epidemiological and pharmacogenetic studies.

3 lso report some of the initial findings from pharmacogenetic studies.

4 clinical information collected from ongoing pharmacogenetic studies.

5 ed populations, which can be used for future pharmacogenetic studies.

6 Pharmacogenetic studies aiming to personalize the treatm

7 Currently, pharmacogenetic studies are at an impasse as the low pre

8 Pharmacogenetics studies are the platform for discoverin

9 Pharmacogenetic studies can be conducted in multicenter

10 Genetic sequence data for pharmacogenetics studies can be complex, and the best in

11 An 8-week, double-blind, randomized pharmacogenetic study compared the widely prescribed ant

12 This pharmacogenetic study evaluated the impact of high-risk

13 the DPYD gene and should be useful in future pharmacogenetic studies examining DPD deficiency.

14 The model was validated by a pharmacogenetic study for two predominant beta-adrenergi

15 morphisms (SNPs) in clinical association and pharmacogenetic studies has created a need for high-thro

16 To date, pharmacogenetic studies have been primarily performed in

17 Pharmacogenetic studies have shown that polymorphisms of

18 Importance: Previous pharmacogenetic studies have shown the prognostic impact

19 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated

20 Pharmacogenetic studies hold the promise of being able t

21 his assay may be useful to complement future pharmacogenetic studies in asthma.

22 Pharmacogenetic studies in larger cohorts are needed to

23 Recent pharmacogenetic studies in mood disorders have reported

24 ould pave the way for the next generation of pharmacogenetic studies in psychiatry.

25 hese data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.

26 ant that samples be collected and stored for pharmacogenetic study in future clinical trials.

27 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri

28 s: in vivo pharmacokinetics studies, in vivo pharmacogenetic studies, in vivo drug interaction studie

29 NP-drug response association dataset for 650 pharmacogenetic studies involving 257 drugs in this upda

30 Concerning pharmacogenetic studies, no association was found for th

31 Pharmacogenetic studies of admixed ethnic groups have be

32 common ethnic groups and facilitate applied pharmacogenetic studies of anticancer drugs.

33 etic studies, review the first generation of pharmacogenetic studies of psychotropic drug response, a

34 selective antagonists for further molecular pharmacogenetic studies of the human prostacyclin recept

35 We conducted a multicenter observational and pharmacogenetic study of 200 patients with DLE treated w

36 participated in a prospective, double-blind, pharmacogenetic study of antidepressant response, and 33

37 We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutram

38 Here we describe a pharmacogenetic study of Li(+) in the nematode Caenorhab

39 An initial pharmacogenetic study of the Sequenced Treatment Alterna

40 ed by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety.

41 Candidate gene pharmacogenetic studies offer a strategy for the rapid a

42 authors discuss methods issues in executing pharmacogenetic studies, review the first generation of

43 nally, the authors discuss unique aspects of pharmacogenetic studies that may distinguish them from s

44 l, Costa-Mattioli et al. present data from a pharmacogenetic study that places a key regulatory event

45 was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Dr

46 ssion Network [DeNT] study; N=332), and 3) a pharmacogenetic study (the Genome-Based Therapeutic Drug

47 Although most pharmacogenetic studies to date have assessed the associ

48 This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon

49 Prior pharmacogenetic studies usually measure exposure via sin

50 Additional, larger pharmacogenetic studies would help to validate these res